Aurora Cannabis ACB
NASDAQ ACB
$4.61 -0.33 (-6.68%)
At close: Nov 16, 2026 · 4:00 PM EST

Aurora Cannabis (ACB) Goodwill impairment charges (2019 - 2026)

Updated

Aurora Cannabis (ACB) recorded Goodwill impairment charges of $13.65 million in fiscal Q4 2026 (quarter ended Mar 31, 2026).

Analysis

Aurora Cannabis (ACB) Goodwill impairment charges (2019 - 2026) Analysis & Trends

For FY2026 (ended Mar 31, 2026), Aurora Cannabis reported Goodwill impairment charges of -$9.54 million.

  • Across earlier fiscal years, Goodwill impairment charges came in at -$24.37 million in FY2024, -$15.57 million in FY2023 and -$947.81 million in FY2022.
  • The fiscal Q4 2026 figure is the highest quarterly Goodwill impairment charges in data going back to fiscal Q3 2019.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Philip Morris International 305.25 Bn 282.25 Bn 7.85 Bn
2 British American Tobacco p.l.c 135.99 Bn 112.36 Bn -
3 Altria 131.53 Bn 118.46 Bn 3.94 Bn
4 Curaleaf Holdings 2.15 Bn 1.77 Bn 170.48 Mn
5 Trulieve Cannabis 2.02 Bn 757.61 Mn 148.02 Mn
6 RLX Technology 1.88 Bn -1.89 Bn 52.74 Mn
7 Green Thumb Industries 1.31 Bn 82.85 Mn 146.79 Mn
8 Cronos 1.21 Bn -1.98 Bn 32.28 Mn
9 Turning Point Brands 997.35 Mn 54.91 Mn 85.18 Mn
10 Aurora Cannabis 261.45 Mn -30.99 Mn 26.82 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 13.65 Mn
Dec 31, 2025 -13.42 Mn
Sep 30, 2025 -9.58 Mn
Jun 30, 2022 -358.80 Mn
Mar 31, 2022 -585.59 Mn
Jun 30, 2021 -33.49 Mn
Dec 31, 2020 -302,986.59
Sep 30, 2020 -2.54 Mn
Jun 30, 2020 -1.29 Bn
Dec 31, 2019 -1.15 Bn
Mar 31, 2019 -6.77 Mn
API Access

Aurora Cannabis Goodwill impairment charges API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=goodwill-impairment-charges&ticker=ACB&period=max&api_key=YOUR_API_KEY